Recent Post
Research reveals a 63 per cent increase in eating disorders during last year’s COVID-19 lockdowns
New research recently published in the Journal of Paediatrics and Child Health reveals how the COVID-19 lockdowns have fuelled a rise in the number of our nation’s reported eating disorders (EDs) The annual presentations of people living with an eating disorder (ED) to a specialist paediatric ED service in Melbourne, increased by 63 per cent…
Read MoreLaunch of world-first expert resource to foster best practice osteoporosis care in the Asia Pacific
Expert collaboration key to reducing burden of disease More than 50 per cent of the world’s hip fractures are expected to occur in the Asia Pacific by the year 2050. In a strong effort to stem the tide, and to promote quality care in osteoporosis, the Asia Pacific Consortium on Osteoporosis (APCO) has launched a…
Read MoreExperts urging Aussies to “Know Your Bones” this World Osteoporosis Day
New AUS report reveals alarming under-investigation &under-treatment of osteoporosis in those at risk Only one in two Australian adults who have broken a bone reported having a bone mineral density test (BMD) to investigate their bone health for the risk of fracture (broken bone), and presence of osteoporosis. Even more concerningly, of those who have…
Read MoreThe lifetime management of anaphylaxis
In Australia, approximately 75% of children with allergies will experience persistent allergies, including anaphylaxis, into adulthood. Anaphylaxis is the most severe form of allergic reaction. It develops rapidly in response to allergen exposure and can be life-threatening or, in some cases, fatal. Living with the risk of anaphylaxis is often associated with a high emotional burden,…
Read MoreNew treatment for severe corneal inflammation from dry eye disease now listed on PBS
Today (Friday, 1 October, 2021), adults living with severe corneal inflammation from dry eye disease (DED) that has not improved with the use of artificial tears, will gain affordable access to a new, once-daily treatment option on the Pharmaceutical Benefits Scheme (PBS). In-licensed for the first time in Australia by Seqirus – a wholly-owned subsidiary…
Read More